AUTOMATED MONITORING OF CHEMOTACTIC CELL MOVEMENT

自动监测趋化细胞运动

• 批准号: 6054380
• 负责人: MICHAEL A LYNES
• 金额: $ 10万
• 依托单位: APPLIED BIOPHYSICS, INC.
• 依托单位国家: 美国
• 财政年份: 2000
• 资助国家: 美国
• 起止时间: 2000-05-01 至 2001-10-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6054380
• 关键词: biomedical automation; biomedical equipment development; cell migration; chemotaxis; electrical impedance; electrodes; high throughput technology; monitoring device

Our phase I objective is to manufacture and test a series of instrument designs that will be capable of automated real time assessment of chemotactic cell movement in culture. Ultimately, we will design systems capable of high throughput screening for chemokines and other cell attractants. Moreover, these systems will facilitate automated assessment of pharmaceuticals that mediate or moderate chemotaxis, as well as drugs that modify non-directional movement (chemokinesis) that can be associated with cancer metastasis. When these objectives have been successfully met, the instrument will be invaluable to pharmaceutical and biotechnology firms that are interestedin manipulation of cell motility that is associated with (for example) inflammation, autoimmune disease, and neoplasia. This work represents and entirely novel approach to the automated measurement of cell movement. PROPOSED COMMERCIAL APPLICATION: The instrument to be developed will enable scientists and clinicians to measure cell movement responses to drugs and other pharmaceuticals. This will vastly improve our assessment of specific disease states (e.g. inflammation, autoimmune disease, and neoplasia) and speed the development of therapeutic drugs for these conditions. The instrument will also facilitate the identification of gene disruptions that impede chemotactic cell responses, enabling the identification of genes that regulate the innate capacity of a cell to respond to external signals.

我们第一阶段的目标是制造和测试一系列仪器设计，这些仪器设计将能够自动实时评估培养物中趋化细胞的运动。最终，我们将设计能够高通量筛选趋化因子和其他细胞引诱剂的系统。此外，这些系统将有助于自动评估介导或调节趋化性的药物，以及改变可能与癌症转移相关的非定向运动（趋化作用）的药物。 当这些目标成功实现时，该仪器对于那些对操纵与炎症、自身免疫性疾病和肿瘤相关的细胞运动感兴趣的制药和生物技术公司来说将具有无价的价值。 这项工作代表了细胞运动自动测量的全新方法。拟议的商业应用：待开发的仪器将使科学家和临床医生能够测量细胞运动对药物和其他药物的反应。这将极大地改善我们对特定疾病状态（例如炎症、自身免疫性疾病和肿瘤）的评估，并加快针对这些疾病的治疗药物的开发。 该仪器还将有助于识别阻碍趋化细胞反应的基因破坏，从而能够识别调节细胞响应外部信号的先天能力的基因。